Investor · 2 deals
Every published round New Enterprise Associates took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Allay Therapeutics | Series C | 16 Sep 2021 | $60m | Participant | Brandon Capital portfolio, Brandon BioCatalyst portfolio | |
| Peplin Inc | Unnamed stage | 18 Aug 2008 | $24m | Participant | GBS Ventures (Mon 18 Aug 2008), GBS Ventures (Mon 18 Aug 2008) |
Companies New Enterprise Associates has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Allay Therapeutics | 16 Sep 2021, Series C | 1 | 0 | |
| Peplin Inc | 18 Aug 2008 | 1 | 0 |
Fund closes reported for New Enterprise Associates, as distinct from the investments it has made.
Companies New Enterprise Associates has backed that another company then bought. An exit for the holding, not a deal New Enterprise Associates did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Peplin Inc | LEO Pharma A/S | Acquisition | 3 Sep 2009 | ~$348.4m |
Stories naming New Enterprise Associates. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Defense startup Singularity has surfaced from stealth, securing a large Series A co-led by two venture firms to scale production of affordable systems that counter cheap drones, with backing from several established investors.
US-Singapore biotech Allay Therapeutics has closed a $60 million Series C round led by Arboretum Ventures, with several healthcare investors taking part, to advance its long-acting post-surgical pain candidate into late-stage trials.
Blackbird introduces Tom Humphrey and Michael Tolo as new investment Principals alongside Tip Piumsomboon, and notes its fourth fund closed at $650 million in late 2020.
Blackbird describes closing its $29M first fund in 2013 and a GP-led secondary where fund investors sold a minority stake to StepStone and HESTA for about $100M, locking in returns while keeping its portfolio.
Also Blackbird Ventures portfolio·Startup Daily·Business News Australia
NEA is reportedly raising close to $7bn split between an early-stage fund and a growth fund, abandoning its longtime single multistage fund approach, according to the piece.